Last week, Fresenius Kabi announced the launch of STIMUFEND (pegfilgrastim-fpgk), a biosimilar to Amgen’s NEULASTA, in the United States. As we previously reported, STIMUFEND was Fresenius Kabi ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Over the years, we have created a portfolio of biosimilar products that are being marketed in several emerging markets. “The launch of our pegfilgrastim through our collaborator in the US in ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...

Check out More Related Studies Published by Fact: The oncology biosimilars market is set to grow from $4.2 billion in 2022 to $12 billion by 2032, with an 11% CAGR. The pegfilgrastim biosimilar ...